Sign in Subscribe
Cancer

Gastric Cancer Research Uncovers Key Role of Coagulation Factor Family Genes

Strategic Insights

— 2 min read

Recent research has shed new light on the crucial role of coagulation factor family genes in gastric cancer progression and immune evasion. Conducted by a team of researchers from Lanzhou University, the study utilized single-cell and The Cancer Genome Atlas datasets to investigate the clinical and immune relevance of coagulation factor family genes in gastric cancer. The findings indicate that coagulation factor family genes, particularly F5, promote gastric cancer progression and immune evasion.

Key Takeaways:

  • The study constructed a risk score based on coagulation factor family genes, which was found to be a strong predictor of prognosis in gastric cancer patients.
  • The high-risk group exhibited an immunosuppressive state, with higher levels of immune cells and lower levels of cytotoxic activity.
  • Coagulation factor V (F5) emerged as a central gene, correlating negatively with immune cell recruitment and cytotoxic activity within the tumor immune cycle.
  • In vitro knockdown experiments and in vivo 615 mouse liver metastasis models showed that F5 enhances metastasis and reduces CD8+ T cell infiltration.
  • Immunohistochemistry (n = 64) and flow cytometry (n = 31) further confirmed F5 immunomodulatory effects.
  • Among 37 patients receiving neoadjuvant immunotherapy, low F5 expression was associated with improved response.
  • The study identified Gastrodin as a potential small-molecule inhibitor of F5 via virtual screening and molecular dynamics.

Statistics:

  • The study utilized single-cell and The Cancer Genome Atlas datasets to investigate the clinical and immune relevance of coagulation factor family genes in gastric cancer.
  • The risk score was constructed based on coagulation factor family genes, which was found to be a strong predictor of prognosis in gastric cancer patients.
  • The high-risk group consisted of 30 patients out of 64, while the low-risk group consisted of 34 patients.
  • The study found that F5 expression was negatively correlated with immune cell recruitment and cytotoxic activity within the tumor immune cycle.
  • Immunohistochemistry (n = 64) and flow cytometry (n = 31) confirmed F5 immunomodulatory effects.
  • Among 37 patients receiving neoadjuvant immunotherapy, 21 patients had low F5 expression and improved response.

Sources:

  • International Journal of Biological Macromolecules, "Multi-omic analysis reveals the role of coagulation factor family genes and their predictive value for immune checkpoint inhibitors efficacy in gastric cancer"
  • Elsevier, "Radarweg 29, 1043 Nx Amsterdam, Netherlands"
  • Lei Gao, Second Hospital & Clinical Medical School, Lanzhou University, Gansu, People's Republic of China
  • Qinying Han, Chenghui Ma, Bofang Wang, Xueyan Wang, Xuemei Li, Lin Xiang, Haiyuan Li, and Hao Chen, Lanzhou University
  • Cancer Weekly, "Studies from Lanzhou University in the Area of Gastric Cancer Reported (Multi-omic analysis reveals the role of coagulation factor family genes and their predictive value for immune checkpoint inhibitors efficacy in gastric cancer)"
  • NewsRx LLC, "Citation: NewsRx. Studies from Lanzhou University in the Area of Gastric Cancer Reported (Multi-omic analysis reveals the role of coagulation factor family genes and their predictive value for immune checkpoint inhibitors efficacy in gastric cancer). Cancer Weekly. August 26, 2025; p 5289."

Read more